Fig. 1From: Safety and immunogenecity of a live attenuated Rift Valley fever vaccine (CL13T) in camelsNeutralizing antibody titres in camels vaccinated with a single and a double dose of live CL13T RVF vaccine. All camels were vaccinated subcutaneously (SC) with a dose of 106TCID50 of the CL13T vaccine. Camels in group 1 received a single dose and camels of group 2 received a booster at day 30 after vaccinationBack to article page